Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Name

As of 08/19/2022

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Nuveen Mid Cap Growth Opportunities Fund

FMECX | Fund

$6.55

$258 M

0.45%

$0.03

1.92%

Vitals

YTD Return

-25.3%

1 yr return

-27.8%

3 Yr Avg Return

5.8%

5 Yr Avg Return

6.7%

Net Assets

$258 M

Holdings in Top 10

24.3%

52 WEEK LOW AND HIGH

$6.7
$5.48
$21.27

Expenses

OPERATING FEES

Expense Ratio 1.92%

SALES FEES

Front Load N/A

Deferred Load 1.00%

TRADING FEES

Turnover 89.00%

Redemption Fee N/A

Min Investment

Standard (Taxable)

$3,000

IRA

$2,500

Fund Classification

Fund Type

Open End Mutual Fund

Name

As of 08/19/2022

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Nuveen Mid Cap Growth Opportunities Fund

FMECX | Fund

$6.55

$258 M

0.45%

$0.03

1.92%

FMECX - Profile

Distributions

  • YTD Total Return -25.3%
  • 3 Yr Annualized Total Return 5.8%
  • 5 Yr Annualized Total Return 6.7%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -1.57%
DIVIDENDS
  • Dividend Yield 0.5%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Nuveen Mid Cap Growth Opportunities Fund
  • Fund Family Name
    Nuveen
  • Inception Date
    Sep 24, 2001
  • Shares Outstanding
    N/A
  • Share Class
    C
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Gregory Ryan

Fund Description

Under normal market conditions, the Fund invests at least 80% of the sum of its net assets and the amount of any borrowings for investment purposes in common stocks of mid-capitalization companies. Mid-capitalization companies are defined as companies that have market capitalizations within the market capitalization range of the companies in the Russell Midcap® Index on the last business day of the month in which its most recent reconstitution was completed. Reconstitution of the index currently is completed in June of each year. On June 30, 2021, the range of the index was $625 million to $61.2 billion. 
In selecting stocks, the Fund’s sub-adviser invests in companies that it believes exhibit the potential for superior growth based on factors such as above-average growth in revenue and earnings, strong competitive position, strong management, and sound financial condition. The Fund’s sub-adviser will generally sell a stock if the stock hits its price target, the company’s fundamentals or competitive position significantly deteriorate, or if a better alternative exists in the marketplace. 
The Fund may invest up to 15% of its total assets in non-dollar denominated equity securities of non-U.S. issuers. In addition, the Fund may invest up to 25% of its assets, collectively, in non-dollar denominated equity securities of non-U.S. issuers and in dollar-denominated equity securities of non-U.S. issuers that are either listed on a U.S. stock exchange or represented by depositary receipts that may or may not be sponsored by a domestic bank. Up to 15% of the Fund’s total assets may be invested in equity securities of emerging market issuers. 
The Fund may utilize options, futures contracts, options on futures contracts, and forward foreign currency exchange contracts (“derivatives”). The Fund may use these derivatives to manage market or business risk, enhance the Fund’s return, or hedge against adverse movements in currency exchange rates. 
Read More

FMECX - Performance

Return Ranking - Trailing

Period FMECX Return Category Return Low Category Return High Rank in Category (%)
YTD -25.3% -84.2% 1797.9% 77.45%
1 Yr -27.8% -60.3% 18.5% 87.56%
3 Yr 5.8%* -0.6% 37.3% 86.41%
5 Yr 6.7%* 3.3% 25.3% 93.83%
10 Yr 8.7%* 6.9% 18.3% 96.15%

* Annualized

Return Ranking - Calendar

Period FMECX Return Category Return Low Category Return High Rank in Category (%)
2023 -52.5% -80.9% 21888.9% 98.95%
2022 13.3% -69.7% 2474.5% 83.82%
2021 -8.9% -100.0% 44.0% 96.99%
2020 -33.8% -100.0% 9.2% 94.90%
2019 -3.8% -33.3% 84.9% 98.13%

Total Return Ranking - Trailing

Period FMECX Return Category Return Low Category Return High Rank in Category (%)
YTD -25.3% -84.2% 1797.9% 72.55%
1 Yr -28.1% -61.9% 73.8% 84.93%
3 Yr 5.8%* -4.2% 37.3% 85.00%
5 Yr 6.7%* 3.3% 25.3% 93.15%
10 Yr 8.7%* 6.9% 18.3% 96.15%

* Annualized

Total Return Ranking - Calendar

Period FMECX Return Category Return Low Category Return High Rank in Category (%)
2023 -52.5% -80.9% 21888.9% 98.95%
2022 13.3% -69.7% 2474.5% 83.82%
2021 -8.9% -100.0% 44.0% 96.99%
2020 -10.6% -100.0% 19.9% 50.78%
2019 23.8% -33.3% 84.9% 50.10%

NAV & Total Return History

FMECX - Holdings

Concentration Analysis

FMECX Category Low Category High FMECX % Rank
Net Assets 258 M 710 K 85.5 B 70.42%
Number of Holdings 67 20 3702 61.96%
Net Assets in Top 10 78.4 M 2.5 K 10.9 B 70.30%
Weighting of Top 10 24.34% 4.3% 92.1% 62.44%

Top 10 Holdings

  1. Synopsys Inc 3.16%
  2. Horizon Therapeutics PLC 2.71%
  3. Horizon Therapeutics PLC 2.71%
  4. Horizon Therapeutics PLC 2.71%
  5. Horizon Therapeutics PLC 2.71%
  6. Horizon Therapeutics PLC 2.71%
  7. Horizon Therapeutics PLC 2.71%
  8. Horizon Therapeutics PLC 2.71%
  9. Horizon Therapeutics PLC 2.71%
  10. Horizon Therapeutics PLC 2.71%

Asset Allocation

Weighting Return Low Return High FMECX % Rank
Stocks 		99.13% 23.99% 100.52% 30.66%
Cash 		0.87% -0.52% 26.94% 68.06%
Preferred Stocks 		0.00% 0.00% 2.30% 65.97%
Other 		0.00% -2.66% 23.05% 66.77%
Convertible Bonds 		0.00% 0.00% 0.40% 61.80%
Bonds 		0.00% 0.00% 44.75% 63.72%

Stock Sector Breakdown

Weighting Return Low Return High FMECX % Rank
Technology 		33.38% 0.04% 62.17% 37.24%
Healthcare 		17.93% 0.00% 43.77% 48.48%
Industrials 		17.55% 0.00% 38.23% 26.16%
Consumer Cyclical 		14.74% 0.00% 57.41% 44.30%
Financial Services 		4.39% 0.00% 43.01% 72.23%
Energy 		3.84% 0.00% 62.10% 22.79%
Consumer Defense 		3.66% 0.00% 16.40% 23.60%
Communication Services 		3.03% 0.00% 18.33% 47.99%
Basic Materials 		1.48% 0.00% 17.25% 61.32%
Utilities 		0.00% 0.00% 12.94% 70.79%
Real Estate 		0.00% 0.00% 19.28% 92.13%

Stock Geographic Breakdown

Weighting Return Low Return High FMECX % Rank
US 		97.20% 23.38% 100.52% 22.31%
Non US 		1.93% 0.00% 35.22% 63.56%

FMECX - Expenses

Operational Fees

FMECX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.92% 0.02% 2.69% 6.66%
Management Fee 0.77% 0.00% 1.50% 69.07%
12b-1 Fee 1.00% 0.00% 1.00% 94.40%
Administrative Fee N/A 0.00% 0.40% N/A

Sales Fees

FMECX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 0.00% 5.75% N/A
Deferred Load 1.00% 1.00% 5.50% 70.00%

Trading Fees

FMECX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FMECX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 89.00% 0.00% 417.06% 84.88%

FMECX - Distributions

Dividend Yield Analysis

FMECX Category Low Category High FMECX % Rank
Dividend Yield 0.45% 0.00% 43.03% 65.01%

Dividend Distribution Analysis

FMECX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Quarterly Annually

Net Income Ratio Analysis

FMECX Category Low Category High FMECX % Rank
Net Income Ratio -1.57% -2.24% 2.75% 94.96%

Capital Gain Distribution Analysis

FMECX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

Distributions History

View More +

FMECX - Fund Manager Analysis

Managers

Gregory Ryan

Start Date

Tenure

Tenure Rank

Mar 19, 2019

3.2

3.2%

GREGORY J. RYAN, CFA Greg is portfolio manager of the Small Cap Select Strategy and related separate account strategies. He joined the Small Cap Select Team in 2013. In addition, he is a senior research analyst for the Small Cap Growth Opportunities Team, specializing in the industrials sector. Greg began working in the financial industry in 1998. Prior to joining the firm in 2007, he was a small-cap equity analyst for industrials, financials, and healthcare for Gabelli Woodland Partners. Greg has also worked as a financial analyst manager with U.S. Bank and as a securities specialist/financial analyst with Fiduciary Counseling. Greg received a B.S. in finance from Winona State University and an M.B.A. in finance from the University of St. Thomas. He holds the Chartered Financial Analyst designation and is a member of the CFA Institute and the CFA Society of Minnesota.

Bihag Patel

Start Date

Tenure

Tenure Rank

Feb 28, 2020

2.25

2.3%

Bihag is a portfolio manager of Nuveen's Mid Cap Growth Opportunities strategy. In addition, he is a senior equity research analyst for Nuveen’s mid-and large-cap research team, specializing in the healthcare sector. Prior to joining the firm in 2014, Bihag was a senior portfolio manager for a small-cap growth strategy at Fort Washington Investment Advisors in Columbus, Ohio, focused on the healthcare sector. He was also a portfolio manager and senior equity analyst at Banc One Investment Advisors, where he followed the biotechnology and pharmaceutical industries. Before his career in the investment industry, he held several healthcare-related consultant roles at Ernst & Young and Aurora Health Care. He started his career in research and test development at Manpower Inc. He began working in the investment industry in 1998. Bihag graduated with a B.A. in Mathematics from the University of Minnesota. He holds the CFA designation and is a member of the CFA Institute.GBI-1100265PR-E0320P

Tenure Analysis

Category Low Category High Category Average Category Mode
0.04 36.3 8.93 1.47

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.